🟢 Crispr Therapeutics is trading 12% up today as markets rebound after the Federal Reserve decision

Crispr Therapeutics is trading 11.99% up now at $58.47 as U.S. markets recover after the Federal Reserve’s September 16 policy decision.

• Stronger risk appetite is lifting growth-oriented biotechnology shares.
• The Nasdaq, S&P 500, and biotech sector are all higher.
• No clear company-specific announcement was identified on September 17; recent coverage centers on the September 14 Morgan Stanley presentation and existing pipeline catalysts.